Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes

Physiol Rep. 2024 Apr;12(7):e16010. doi: 10.14814/phy2.16010.

Abstract

Aldosterone has been suggested to be involved in the microvascular complications observed in type 2 diabetes. We aimed to investigate the effect of mineralocorticoid receptor (MR) blockade on endothelial function in individuals with type 2 diabetes compared to healthy controls. We included 12 participants with type 2 diabetes and 14 controls. We measured leg hemodynamics at baseline and during femoral arterial infusion of acetylcholine and sodium nitroprusside before and 8 weeks into treatment with MR blockade (eplerenone). Acetylcholine infusion was repeated with concomitant n-acetylcysteine (antioxidant) infusion. No difference in leg blood flow or vascular conductance was detected before or after the treatment with MR blockade in both groups and there was no difference between groups. Infusion of n-acetylcysteine increased baseline blood flow and vascular conductance, but did not change the vascular response to acetylcholine before or after treatment with MR blockade. Skeletal muscle eNOS content was unaltered by MR blockade and no difference between groups was detected. In conclusion, we found no effect of MR blockade endothelial function in individuals with and without type 2 diabetes. As the individuals with type 2 diabetes did not have vascular dysfunction, these results might not apply to individuals with vascular dysfunction.

Keywords: aldosterone; endothelial function; mineralocorticoid receptor; type 2 diabetes.

MeSH terms

  • Acetylcholine / administration & dosage
  • Acetylcholine / pharmacology
  • Acetylcholine / therapeutic use
  • Acetylcysteine
  • Aldosterone
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Receptors, Mineralocorticoid*

Substances

  • Acetylcholine
  • Acetylcysteine
  • Aldosterone
  • Receptors, Mineralocorticoid